logo
logo

Glycoera Ag Raises Chf 45 Million (Us$ 49 Million) Series A Financing To Develop Novel Biologics Based On Innovative Glycoengineering Platform

Nov 05, 2021•over 3 years ago

Round Type

series a

Schlieren

Description

GlycoEra AG announced today the close of a CHF 45 million ($49 million) Series A financing round, co-led by renowned US and European life science investors, 5AM Ventures, Roche Venture Fund and Sofinnova Partners. LimmaTech Biologics AG, from which GlycoEra was spun-out, also participated in this round. The proceeds will be used to support the growth of the company and to demonstrate the breadth and value of its CustomGlycan Platform technology in developing assets that can unlock unique biological activities for therapeutic targets in several disease indications.

Company Information

Company

Glyco Era Ag

Location

Schlieren, Zurich, Switzerland

About

GlycoEra’s innovative CustomGlycan platform unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics for a broad range of indications. Founded by a highly experienced team of glycoengineering leaders, the company is based in Schlieren, Switzerland. For further information, please visit www.glycoera.com.